Literature DB >> 23370236

Target watch: Drugging the epigenome.

Samia Burridge.   

Abstract

Mesh：

Year:  2013        PMID： 23370236     DOI： 10.1038/nrd3943

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

Review 1.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694
  1 in total
  12 in total

1.  The epigenetics pipeline.

Authors:  Vivian A DeWoskin; Ryan P Million
Journal:  Nat Rev Drug Discov       Date:  2013-09       Impact factor: 84.694

Review 2.  Drugging the pain epigenome.

Authors:  Ellen Niederberger; Eduard Resch; Michael J Parnham; Gerd Geisslinger
Journal:  Nat Rev Neurol       Date:  2017-05-26       Impact factor: 42.937

3.  Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm.

Authors:  J Menezes; F Acquadro; M Wiseman; G Gómez-López; R N Salgado; J G Talavera-Casañas; I Buño; J V Cervera; S Montes-Moreno; J M Hernández-Rivas; R Ayala; M J Calasanz; M J Larrayoz; L F Brichs; M Gonzalez-Vicent; D G Pisano; M A Piris; S Álvarez; J C Cigudosa
Journal:  Leukemia       Date:  2013-09-27       Impact factor: 11.528

4.  Dual epigenetic modifiers for cancer therapy.

Authors:  Edurne San José-Enériz; Obdulia Rabal; Xabier Agirre; Julen Oyarzabal; Felipe Prosper
Journal:  Mol Cell Oncol       Date:  2017-06-20

5.  Mapping the new molecular landscape: social dimensions of epigenetics.

Authors:  Martyn Pickersgill; Jörg Niewöhner; Ruth Müller; Paul Martin; Sarah Cunningham-Burley
Journal:  New Genet Soc       Date:  2013-12-09

6.  Covalent adduct formation between the antihypertensive drug hydralazine and abasic sites in double- and single-stranded DNA.

Authors:  Douglas Melton; Calvin D Lewis; Nathan E Price; Kent S Gates
Journal:  Chem Res Toxicol       Date:  2014-11-18       Impact factor: 3.739

Review 7.  Chronic neutrophilic leukemia: a clinical perspective.

Authors:  Juliane Menezes; Juan Cruz Cigudosa
Journal:  Onco Targets Ther       Date:  2015-09-01       Impact factor: 4.147

8.  Expanding the druggable space of the LSD1/CoREST epigenetic target: new potential binding regions for drug-like molecules, peptides, protein partners, and chromatin.

Authors:  James C Robertson; Nate C Hurley; Marcello Tortorici; Giuseppe Ciossani; Maria Teresa Borrello; Nadeem A Vellore; A Ganesan; Andrea Mattevi; Riccardo Baron
Journal:  PLoS Comput Biol       Date:  2013-07-18       Impact factor: 4.475

9.  CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia.

Authors:  J Menezes; H Makishima; I Gomez; F Acquadro; G Gómez-López; O Graña; A Dopazo; S Alvarez; M Trujillo; D G Pisano; J P Maciejewski; J C Cigudosa
Journal:  Blood Cancer J       Date:  2013-11-08       Impact factor: 11.037

10.  Molecular dynamics simulations indicate an induced-fit mechanism for LSD1/CoREST-H3-histone molecular recognition.

Authors:  Nadeem A Vellore; Riccardo Baron
Journal:  BMC Biophys       Date:  2013-11-25       Impact factor: 4.778
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.